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TECHNICAL_NOTE
Measurement of urinary para-aminohippuric acid in
glycosuric diabetics
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Department of Paediatrics and Unit for Metabolic Medicine, UMDS, Guy's Campus, London, United Kingdom
The observation that hyperglycemia may reduce the renal
clearance of para-aminohippuric acid (PAH) dates back to 1944
[I], This and similar findings [2, 3] have been interpreted as the
result of physiological competition between renal tubular glu-
cose reabsorption and PAH secretion [4]. Similar problems
have, however, not been encountered when the clearance of
radioactive iodohippuran has been used to estimate renal plasma
flow (RPF). The different results obtained using different tech-
niques have contributed to the considerable uncertainty sur-
rounding the evaluation of RPF in diabetics who have been
reported as either having normal [5], high [61 or low [7] RPF.
Recently, Dalton et a! [8], in a study of renal hemodynamics in
normal subjects at different levels of stable hyperglycemia,
found that a marked fall in the clearance of free PAH occurred
only in the presence of glycosuria. In a preliminary study in our
laboratory we observed a physiologically improbable fall in
PAH clearance during hyperglycemia and glycosuria in insulin-
dependent diabetics. Urine aliquots taken into tubes containing
sodium hydroxide (NaOH) to measure urinary concentrations
of j32-microglobulin, a protein which is unstable at low pH,
yielded PAH concentrations in the expected range.
To clarify the reasons for these findings we have performed a
series of in vivo and in vitro studies which were aimed at
explaining the fall of free PAH concentrations in urine during
hyperglycemia with glycosuria, and at exploring possible solu-
tions to the fluctuation.
Methods and patients
Six male insulin-dependent diabetics performed the study
which was approved by the Guy's Hospital Ethical Committee.
They had no evidence of clinical proteinuria, were aged be-
tween 18 and 33 years (mean 26 years), and with duration of
diabetes ranging between 6 and 14 years (mean 9 years).
Patients were maintained euglycemic by an insulin infusion
overnight, and rendered hyperglycemic by a graded intravenous
dextrose infusion the morning of the test [9]. A classical
constant infusion renal clearance procedure was then per-
formed during a steady state of water diuresis, using PAH
(Sodium Aminohippurate, Merck, Sharp & Dohme Ltd,
Hoddesdon, UK). After 45 minutes equilibration, urine was
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collected during six consecutive, accurately timed clearance
periods of approximately 20 minutes each and blood was taken
at the mid-point of each clearance period for measurement of
PAH and glucose. Two 3.5 ml aliquots of urine were taken; one
without additives, and one collected into a tube containing 20 tl
of 4 M NaOH. The pH of this latter collection exceeded 9 in the
majority of the samples. The samples were then frozen within 6
hours and kept at —20°C until assayed, between 8 and 26 weeks
later.
Prior to PAH assay 200 1.d of each untreated urine sample
were mixed with 10 tl of 0.4 M NaOH or 10 pA concentrated
(11.6 M) hydrochloric acid (HCI, Analar) in capped polypropyl-
ene tubes and heated in a dry block for 10 minutes at 70°C. The
samples were then cooled and mixed. Thus, PAH was mea-
sured in untreated urine samples, in urine collected in NaOH
and in urine treated after storage with NaOH or HCI.
Addition of PAll and glucose to control urine
A solution containing 58.2 mg/dl PAH and 360 mg/dl glucose
was made up in normal control urine diluted 1: 10 in distilled
water (final creatinine concentration 0.9 mmol/liter), to simulate
the sample conditions associated with forced diuresis. The pH
of this solution was 5.9. Several 3.5 ml aliquots of this solution
were prepared and 20 pA of 4 M NaOH was added to half of
them. The pH of aliquots containing NaOH was greater than II.
PAH was measured after incubation at 37°C for 20 minutes (to
simulate the in vivo period during which urine resides in the
bladder at body temperature) in untreated urine and then after
six hours at room temperature and 1, 3, 8, and 26 weeks at
—20°C in both untreated urine and urine containing NaOH. As
control experiments aliquots of urine from control and glycos-
uric diabetic subjects not receiving PAH infusion as well as
aliquots of an aqueous solution (pH 3.1) containing PAH (100
mg/dl) and glucose (1.8 g/dl) were stored at —20°C for 20 weeks
and assayed by high pressure liquid chromatography (HPLC).
All determinations were made in triplicate.
Measurements
PAH was measured according to the method of Brun [10],
adapted for use on a centrifugal analyzer (COBAS Bio, Roche
Diagnostica Ltd, Welwyn Garden City, UK) and directly on
centrifuged urine samples by HPLC [Ill. The detection wave-
length was 275 nm and the acetonitrile concentration in the
elution buffer was increased to 5.7% for optimal separation of
free PAH and PAH-glucose conjugate (PAH-G).
117
118 Dalton et al: Urinary PAH in diabetics
Table 1. Plasma and urine concentrations of glucose and PAH in 6 insuun-dependent diabetic patients
Glucose PAH ,ngldl
mmol/liter .Unne collected Urine treated .Urine treated .Storage time
Subject Plasma Urine Plasma in NaOH Urine untreated with NaOH with HCI weeks
1 15.1 15.6 1.3 67.1 4.8 4.8 68.6 26
2 15.0 22.7 1.6 109.3 11.2 10.8 107.3 22
3 13.6 27.9 1.5 112.1 28.4 21.2 117.4 8
4 13.0 28.2 2.3 89.5 8.9 7.4 87.0 14
5 16.7 19.5 1.3 81.9 11.1 9.6 87.2 21
6 15.1 23.4 1.5 83,6 13.7 13.9 87.4 17
Mean 14.8 22.9 1.6 90.6 13.0 11.3 92.5
SEM 0.5 2.0 0.2 7.0 3.3 2.3 7.1
Urines were collected in NaOH, untreated, and treated with NaOH or HCI before assay.
Ic)
Table 2. The effect of storage with and without NaOH on measurable
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Fig. L HPLC traces of PAH and PAH-glucose (PAH-G) conjugate in
(A) untreated urine, (B) urine collected in NaOH, (C) urine treated with
NaOH after storage, and (D) urine acid hydrolyzed after storage.
Glucose was measured in plasma and urine by a glucose
oxidase method (Yellow Springs YSI 23AM, Yellow Springs,
Ohio, USA). In the studies in diabetic patients the mean urine
and plasma concentrations of PAH and glucose of all six
collection periods for each patient are presented. Data were
analyzed using the paired t-test and the significance level taken
at 1% because of multiple comparisons.
Results
Table 1 shows plasma and urinary glucose concentrations and
the levels of PAH in plasma and in urine collected in NaOH,
untreated, and treated with NaOH or HC1 before assaying.
All six subjects were hyperglycaemic (range 13.0 to 16.7
mmol/liter) and had significant glycosuria (range 15.6 to 28.2
mmollliter). Mean plasma PAH was 1.6 mg/dl (range 1.3 to 2.3).
In the urine, PAH concentrations were significantly lower (P <
0.001) in the untreated aliquots compared to those collected into
NaOH. Addition of NaOH to the untreated urine before assay
° This sample was hydrolyzed with HCI as described in methods and
reanalyzed PAH was 58.8 mg/dl.
did not result in recovery of PAH. By contrast, acid hydrolysis
of the untreated urine prior to assay led to PAH concentrations
strictly comparable to those found in urine collected in NaOH.
Figure 1 shows the results obtained when urinary PAH was
determined by HPLC. In all the untreated urine samples free
PAH was extremely low, confirming the results obtained using
the Brun method. In these urines a second peak (PAH-G),
chromatographing slightly earlier than PAH, was observed.
This peak was virtually absent in the urine samples collected in
NaOH or those subsequently acid hydrolyzed, but it was
present in the urine samples treated with NaOH prior to assay.
The elution fraction corresponding to the PAH-G peak was
collected and analyzed for PAH and glucose; both were barely
detectable. Following acid hydrolysis of the peak fraction
equimolar amounts of glucose and PAH were recovered.
Table 2 shows the effect of storage with and without NaOH of
a control urine solution containing PAH (58.2 mg/dl) and
glucose (360 mg!dl). After 8 and 26 weeks of storage at —20°C,
measured free PAH concentrations in the urine without NaOH
were 40% and 70% lower, respectively, than the initial PAH
value. By contrast, no change in PAH concentration was
detected in the urine solution containing NaOH. At 26 weeks
the untreated urine was acid hydrolyzed, which led to total
recovery (58.8 mg/dl) of the free PAH. HPLC analysis of these
samples confirmed the loss of free PAH in the untreated urine
and the appearance of the PAH-G peak. No peak with this
retention time was seen in the chromatograms of stored urine
from control or glycosuric diabetic subjects not containing
PAH, but a similar peak was present in the aqueous solution of
PAH and glucose stored at —20°C (data not shown). Acid
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hydrolysis resulted in the loss of the PAH-G peak and recovery
of free PAH and glucose confirming that the PAH-G peak
represents an adduct of PAH and glucose.
Discussion
This study demonstrates that the lower free PAH concentra-
tions found in glycosuric urine in man are the result of reaction
between glucose and PAH during storage. That PAH and
glucose might react, presumably to form a Schiff base, was
originally suggested by Baldwin et al [12] who noticed a fall in
PAH concentration in solutions of glucose and PAFI prepared
for infusion. Recently, Lote, McVicar and Yardley [13] con-
firmed that glucose and PAH will react in vitro, but considered
the reaction too slow to be a problem under most experimental
conditions. In their physiological studies in hyperglycemic rats
they concluded that the fall in PAH clearance resulted from
competition between renal tubular reabsorption of glucose and
secretion of PAH, in agreement with previous views [4].
In man, however, a series of observations argue against this
interpretation. Firstly, the fall in PAH clearance observed
during hyperglycemia only occurs when the hyperglycemia is
accompanied by glycosuria and is due to an apparent decrease
in urinary PAH [8], an effect which could be abolished by acid
hydrolysis [14]. No loss of urine free PAH was seen in either
normoglycemic or hyperglycemic non-glycosuric subjects [8].
Secondly, no effect of hyperglycemia or glycosuria has been
recognized when renal plasma flow is measured using radioac-
tive iodohippuran [6], although PAH and iodohippuran are both
secreted by the weak organic acid transporter. Finally, the renal
extraction of PAH, measured using classical renal arteriove-
nous PAH concentration differences, has been shown to be
normal in diabetes [15].
Our findings with HPLC analysis of urine PAH demonstrat-
ing the existence of a peak in glycosuric urine, which may be
hydrolyzed to glucose and PAH, strongly suggest the formation
of a PAH adduct, probably a Schiff base. The PAH and glucose
are reacting with each other is further supported by our
experiment showing the formation of the PAH-G peak in an
aqueous solution containing PAH and glucose alone. Chemical
methods for the measurement of PAH, such as those described
by Bratton and Marshall [16] and Brun [101, depend on the
availability of the para-amino group for reaction. Schiff base
formation between the para-amino group of PAH and the
aldehyde group of open chain glucose would occlude the amine
group and reduce measurable free PAH.
Collection of urine in NaOH or acid hydrolysis of stored
glycosuric urine maintained and respectively restored the ex-
pected concentrations of PAH. HPLC analysis of urine submit-
ted to these procedures showed a virtual abolition of the
PAR-U peak seen in untreated glycosuric urine. Schiff base
formation is a reversible reaction dependent on initial nucleo-
philic attack by the free amine group of PAH on the aldehyde
group of open-chain glucose. This step is promoted in alkaline
conditions, whereas the final dehydration step is dependent on
acid conditions. Alkalinization of urine to a pH of 9 or greater
prevented the reaction totally, presumably by providing condi-
tions in which the final dehydration step could not take place.
Certainly, alkaline hydrolysis of the complex does not take
place since alkalinization of the urine after the reaction between
PAH and glucose has occurred is unable to reverse it. By
contrast acid hydrolysis restores free PAH by reducing the
availability of the nucleophile and allowing the back reaction to
predominate.
The ability of NaOH to prevent the formation of a PAH-G
peak excludes the possibility of pre-renal or intra-renal reaction
between glucose and PAH as an explanation of our data. In this
communication the various factors which influence the reaction
between PAH and glucose, such as concentration, pH, temper-
ature, and time, have not been considered in detail, but both the
in vivo and in vitro studies demonstrate that measurable free
PAH declines in glycosuric urine stored at —20°C. Under our
experimental conditions several weeks were required to detect
a fall in free PAH concentration. There was no detectable loss
at 37°C or room temperature within the time restrictions of our
in vitro experiment.
In conclusion, this series of experiments taken together
support the notion that no significant impairment of tubular
PAH secretion takes place during hyperglycemia. The loss of
free PAH in glycosuric urine, and the resultant apparent low-
ering of PAH clearance, occurs in vitro during storage and not
in vivo during the clearance procedure. The in vitro conversion
of free PAR to an analytically silent adduct can be prevented by
alkalinizing the urine immediately after collection. Once the
reaction between PAH and glucose has taken place, recovery of
free PAH can be achieved by acid hydrolysis of the urine prior
to assay.
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